# BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)

> **NCT01903265** · PHASE2,PHASE3 · COMPLETED · sponsor: **Tonix Pharmaceuticals, Inc.** · enrollment: 205 (actual)

## Conditions studied

- Primary Fibromyalgia

## Interventions

- **DRUG:** TNX-102 SL 2.8mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01903265
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-07
- **Final completion:** 2014-09
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2016-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01903265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01903265, "BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01903265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*